Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Republic of Korea.
Department of Chemistry, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Republic of Korea.
Biosensors (Basel). 2024 Feb 29;14(3):129. doi: 10.3390/bios14030129.
Vancomycin (VAN) is an effective antibiotic against Gram-positive bacteria and the first-line therapy to prevent and treat methicillin-resistant (MRSA) and severe infections. However, low concentrations of VAN can result in resistant strains. High doses of VAN can cause nephrotoxicity and ototoxicity; thus, VAN is a representative drug for which drug monitoring is recommended. Several methods have been proposed to detect VAN. Among them, lateral flow immunoassays (LFIAs) have advantages, such as simple and user-friendly operation, low sample volume requirement, and cost effectiveness. In this study, we developed an LFIA capable of rapid on-site detection such that the VAN concentration in plasma could be monitored within 20 min by a one-step detection process using whole blood without plasma separation. VAN can be detected in whole blood over a wide range of concentrations (20-10,000 ng/mL), and the LFIA reported here has a detection limit of 18 ng/mL. The applicability of the developed LFIA compared to the results of measuring VAN with a commercial enzyme-linked immunosorbent assay kit showed a satisfactory correlation (Spearman's rho, ρ = 0.891). Therefore, the developed LFIA enables rapid and wide-range VAN detection in whole blood and can aid in drug monitoring to evaluate patients' responses to treatment.
万古霉素(VAN)是一种有效的抗革兰氏阳性菌抗生素,也是预防和治疗耐甲氧西林金黄色葡萄球菌(MRSA)和严重感染的一线治疗药物。然而,低浓度的 VAN 可能导致耐药菌株的产生。高剂量的 VAN 会导致肾毒性和耳毒性;因此,VAN 是一种推荐进行药物监测的代表性药物。已经提出了几种检测 VAN 的方法。其中,侧向流动免疫分析(LFIAs)具有操作简单、用户友好、样品体积需求低、成本效益高等优点。在本研究中,我们开发了一种能够快速现场检测的 LFIA,通过一步检测过程,无需血浆分离,即可在 20 分钟内监测血浆中的 VAN 浓度。VAN 可以在全血中检测到广泛的浓度范围(20-10,000ng/mL),本研究报告的 LFIA 的检测限为 18ng/mL。与使用商业酶联免疫吸附测定试剂盒测量 VAN 的结果相比,所开发 LFIA 的适用性显示出令人满意的相关性(Spearman rho,ρ=0.891)。因此,所开发的 LFIA 能够在全血中快速、广泛地检测 VAN,并有助于药物监测,以评估患者对治疗的反应。